^
Association details:
| Biomarker: | MELTF expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | SGN-CD228A (Microtubule inhibitor, CD228-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models
Published date:
02/07/2023
Excerpt:
In vivo, CD228 expression was important for response to SGN-CD228A but was not well-correlated across all tumor types, suggesting that other factors associated with ADC activity are important. Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity.
DOI:
10.1158/1535-7163.MCT-22-0401
